PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 10, 2026Advanced Science1 citationsOpen Access

SDS‐CRISPR for Single‐Nucleotide Variant Detection

View Full Paper
XGX. GuanCGChong GuoJZJiongyu Zhang

Key Points

  • The research aims to enhance the detection accuracy of single-nucleotide variants using a novel CRISPR-based approach.
  • Introduced Structure-Disruption-Sensitive CRISPR (SDS-CRISPR) for allele discrimination.
  • Applied AlphaFold3 modeling for structural insights.
  • Combined SDS-CRISPR with a lateral-flow strip and AI-assisted smartphone reader.
  • Clinical validation on 43 glioma tissue samples and plasma cfDNA testing.
  • Achieved attomole sensitivity and 0.01% variant frequency for IDH1 allele detection.
  • Demonstrated high concordance with immunohistochemistry results in glioma samples.
  • Validated mutation fractions in plasma cfDNA consistent with next-generation sequencing.
  • Generalized across targets, discriminating microRNA isoforms and identifying HIV-1 mutations.

Abstract

The CRISPR-Cas12a system offers a promising platform for simple and sensitive nucleic acid diagnostics, including tumor-associated variant detection and infectious agent identification. However, its intrinsic mismatch tolerance limits its ability to accurately detect single-nucleotide variants (SNVs). Here, we introduce Structure-Disruption-Sensitive CRISPR (SDS-CRISPR), a programmable CRISPR-Cas12a approach that achieves highly precise allele discrimination. Guided by AlphaFold3 modeling and bioinformatic analysis, we uncover how split structural design and ionic modulation reconfigure Cas12a conformations, elucidating the structural basis of SNV discrimination in SDS-CRISPR. We apply SDS-CRISPR to detect IDH1WT and IDH1R132H alleles with attomole sensitivity and 0.01% variant frequency. To facilitate intraoperative use, we combine SDS-CRISPR with a lateral-flow strip and an artificial intelligence-assisted smartphone reader, enabling on-site detection within 20 min. Clinical validation with 43 glioma tissue samples shows high concordance with immunohistochemistry, while plasma cfDNA testing demonstrates mutation fractions consistent with next-generation sequencing. Beyond glioma, SDS-CRISPR generalizes across molecular targets, discriminating microRNA isoforms and identifying HIV-1 drug-resistance mutations. Together, these results establish SDS-CRISPR as a universal, mechanistically informed, and clinically actionable framework for precision molecular diagnostics.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Guan et al. (2026) studied this question.

synapsesocial.com/papers/69d894ce6c1944d70ce05bedhttps://doi.org/10.1002/advs.75149
Ask AI
Helpful
Bookmark
Share
View Full Paper